TP53 and non-small cell lung carcinoma: Our data contrasted with the report from Labbé et al. (6) who found that concomitant TP53 mutation status was dissociated from OS in patients with EGFR-mutant NSCLC at an early stage who underwent primary surgical resection and received adjuvant chemotherapy.